Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FATE: Faricimab vs Aflibercept Treat-and-Extend in nAMD and DME
DRKS00031548Phase 4Recruiting
- Sponsor
- Augenklinik der Medizinischen Hochschule Hannover
- Start
- Mar 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of faricimab and aflibercept in exudative macular degeneration, diabetic macular edema (DME) and diabetic retinopathy (DR) (2 arms), sponsored by Augenklinik der Medizinischen Hochschule Hannover. Started Mar 2023; status: recruiting.
02
Drugs
faricimabaflibercept
03
Conditions
exudative macular degenerationdiabetic macular edema (DME)diabetic retinopathy (DR)
Beyond the preview
Go deeper on DRKS00031548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on DRKS00031548.